Clinical Trial Update: A Phase IIa, Single-arm, Open-label Clinical Study to Evaluate the Efficacy, Safety and PK of CVM-1118 in Combination With Sintilimab and TACE in Participants With Incurable/Non-metastatic HCC [Phase 2]

View source ↗

Summary

Phase IIa, single-arm, open-label study to evaluate CVM-1118 in combination with sintilimab and TACE for incurable/non-metastatic hepatocellular carcinoma; tria…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• CVM-1118
• Sintilimab (sintilimab)

Snippet

Sponsor: TaiRx, Inc. | Conditions: HCC - Hepatocellular Carcinoma | Phase 2 | Status: RECRUITING